Antisense oligodeoxynucleotide combination therapy of primary chronic myelogenous leukemia blast crisis in SCID mice

Blood

Volumn 88, Issue 3, 1996, Pages 1005-1012

  Skorski, Tomasz ^b   Nieborowska Skorska, Malgorzata ^b   Wlodarski, Pawel ^b   Zon, Gerald ^b   Iozzo, Renato V ^b   Calabretta, Bruno ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; COMPLEMENTARY DNA; MESSENGER RNA; PHOSPHOROTHIOIC ACID DERIVATIVE;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CANCER IMMUNOTHERAPY; CHRONIC MYELOID LEUKEMIA; CLONOGENIC ASSAY; COMBINED IMMUNODEFICIENCY; CONTROLLED STUDY; DOWN REGULATION; DRUG TARGETING; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0029768861     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v88.3.1005.1005     Document Type: Article

References (35)

1. bcr/abl implication for RAS-dependent Philadelphia chromosome positive cell growth. J Exp Med 173:1855, 1994
2. Sawyers CL, McLaughlin J, Witte ON: Genetic requirement for RAS in the transformation of fibroblasts and hematopoietic cells by the bcr-abl oncogene. J Exp Med 181:307, 1995
3. Skorski T, Nieborowska-Skorska M, Szczylik C, Kanakaraj P, Perrotti D, Zon G, Gewirtz AM, Perussia B, Calabretta B: C-RAF-1 serine/threonine kinase is required in bcr/abl-dependent and normal hematopoiesis. Cancer Res 55:2275, 1995
4. Skorski T, Kanakaraj P, Nieborowska-Skorska M, Ratajczak MZ, Wen S-C, Zon G, Gewirtz AM, Perussia B, Calabretta B: Phosphatidylinositol-3 kinase activity is regulated by bcr/abl and is required for the growth of Philadelphial chromosome-positive cells. Blood 86:726, 1995
5. Sawyers CL, Callahan W, Witte ON: Dominant negative myc blocks transformation by abl oncogenes. Cell 70:801, 1992
6. Afar DEH, Goga A, McLaughlin J, Witte ON, Sawyers CL: Differential complementation of bcr-abl point mutants with c-myc. Science 264:424, 1994
7. Calabretta B: Inhibition of protooncogene expression by antisense oligodeoxynucleotides: Biological and therapeutic implications. Cancer Res 51:4505, 1991
8. Stein CA, Cheng Y-C: Antisense oligonucleotides as therapeutic agents - Is the bullet really magical? Science 261:1004, 1993
9. Ratajczak MZ, Kant JA, Luger SM, Hijiya N, Zhang J, Zon G, Gewirtz AM: In vivo treatment of human leukemia in a SCID mouse model with c-myb antisense oligodeoxynucleotides. Proc Natl Acad Sci USA 89:11823, 1992
10. Hijiya N, Zhang J, Ratajczak MZ, Kant JA, de Riel K, Herlyn M, Zon G, Gewirtz AM: Biologic and therapeutic significance of myb expression in human melanoma. Proc Natl Acad Sci USA 91:4493, 1994
11. 1 leukemia cell growth in mice by bcr-abl antisense oligodeoxynucleotide. Proc Natl Acad Sci USA 81:4504, 1994
12. Szczylik C, Skorski T, Nicolaides NC, Manzella L, Malaguarnera L, Venturelli D, Gewirtz AM, Calabretta B: Selective inhibition of leukemic cell proliferation by bcr-abl antisense oligodeoxynucleotides. Science 253:562, 1991
13. Skorski T, Szczylik C, Malaguarnera L, Calabretta B: Genetargeted specific inhibition of chronic myeloid leukemia cell growth by bcr/abl antisense oligodeoxynucleotides. Folia Histochem Cytobiol 28:85, 1991
14. O'Brien SG, Kirkland MA, Melo JV, Davidson RJ, McDonald C, Goldman JM: Antisense bcr-abl oligomers cause non-specific inhibition of chronic myeloid leukemic cell lines. Leukemia 8:2156, 1994
15. Maekawa T, Kimura S, Hirakawa K, Murakami A, Zon G, Abe T: Sequence specificity on the growth suppression and induction of apoptosis of chronic myeloid leukemia cells by bcr-abl antisense phosphorothioate oligodeoxynucleotides. Int J Cancer 62:63, 1995
16. Brown DA, Kang S-H, Gryaznov SM, DeDionisio L, Heidenreich D, Sullivan S, Xu X, Nerenberg MI: Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding. J Biol Chem 269:26801, 1994
17. Guvakova MA, Yakubov LA, Vlodavsky I, Tonkinson JL, Stein CA: Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix. J Biol Chem 270:2620, 1995
18. Lipsick JS, Boyle WJ: c-myb protein expression is a late event during T-lymphocyte activation. Mol Cell Biol 7:3358, 1987
19. Thiele CJ, Cohen PS, Israel M: Regulation of c-myb expression in human neuroblastoma cells during retinoic acid-induced differentiation. Mol Cell Biol 8:1677, 1988
20. Giles RV, Spiller DG, Green JA, Clark RE, Tidd PM: Optimization of antisense oligodeoxynucleotide structure for targeting bcr-abl mRNA. Blood 86:744, 1995
21. Skorski T, Nieborowska-Skorska M, Campbell K, Iozzo RV, Zon G, Darzynkiewicz Z, Calabretta B: Leukemia treatment in SCID mice by antisense oligodeoxynucleotides targeting cooperating oncogenes. J Exp Med 182:1645, 1995
22. Agrawal S, Temsamani J, Tang JY: Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci USA 88:7595, 1991
23. Leonetti C, D'Agnano I, Lozupone F, Valentini A, Geiser T, Zon G, Calabretta B, Citro G, Zupi G: Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and in mice. J Natl Cancer Inst 88:419, 1996
24. Yaswen P, Stampfer MR, Ghosh K, Cohen IS: Effects of sequence of thioated oligonucleotides on cultured human mammary epithelial cells. Antisense Res Dev 3:67, 1993
25. Burgess TL, Fischer EF, Ross SL, Bready JV, Qian Y-X, Bayewitch LA, Cohen AM, Herrera CJ, Hu SS-F, Kramer TB, Lott FD, Martin FH, Pierce GF, Simonet L, Farrell CL: The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism. Proc Natl Acad Sci USA 92:4051, 1995
26. bcr/abl tyrosine kinase autophosphorylation by oligodeoxynucleotides of defined sequence and backbone structure. Nucleic Acids Res 22:2150, 1994
27. Goga A, McLaughlin J, Afar DEH, Saffran DC, Witte ON: Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene. Cell 82:981, 1995
28. Yamamato S, Yamamato T, Kataoka T, Kuramoto E, Yano O, Tokunaga T: Unique palindromic sequences in synthetic oligonucleotides are required to induce INF and augment IFN-mediated natural killer activity. J Immunol 12:4072, 1992
29. Krieg AM, Yi A-K, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, Klinman DM: CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374:546, 1995
30. Stein CA: Does antisense exist? Nature Med 1:1119, 1995
31. bcr/abl gene of Philadelphia chromosome. Science 247:824, 1990
32. Heisterkamp N, Jenster G, ten Hoeve J, Zovich D, Pattengale PK, Groffen J: Acute leukemia in bcr/abl transgenic mice. Nature 344:251, 1990
33. Elefanty AG, Hariharan IK, Cory S: bcr-abl, the hallmark of chronic myeloid leukemia in man, induces multiple hematopoietic neoplasms in mice. EMBO J 9:1069, 1990
34. Kelliher MA, McLaughlin J, Witte ON, Rosenberg N: Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc Natl Acad Sci USA 87:6649, 1990
35. Caracciolo D, Venturelli D, Valtieri M, Peschle C, Gewirtz AM, Calabretta B: Stage related proliferation activity determines c-myb functional requirements during normal human hematopoiesis. J Clin Invest 85:55, 1990